Logo image of AUPH

AURINIA PHARMACEUTICALS INC (AUPH) Stock Fundamental Analysis

NASDAQ:AUPH - Nasdaq - CA05156V1022 - Common Stock - Currency: USD

7.93  +0.1 (+1.28%)

After market: 7.93 0 (0%)

Fundamental Rating

5

AUPH gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. The financial health of AUPH is average, but there are quite some concerns on its profitability. AUPH is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year AUPH has reported negative net income.
In the past year AUPH had a positive cash flow from operations.
In the past 5 years AUPH always reported negative net income.
AUPH had a negative operating cash flow in each of the past 5 years.
AUPH Yearly Net Income VS EBIT VS OCF VS FCFAUPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

AUPH has a Return On Assets of -4.11%. This is amongst the best in the industry. AUPH outperforms 90.05% of its industry peers.
Looking at the Return On Equity, with a value of -5.81%, AUPH belongs to the top of the industry, outperforming 91.83% of the companies in the same industry.
Industry RankSector Rank
ROA -4.11%
ROE -5.81%
ROIC N/A
ROA(3y)-23.51%
ROA(5y)-23.99%
ROE(3y)-28.37%
ROE(5y)-27.98%
ROIC(3y)N/A
ROIC(5y)N/A
AUPH Yearly ROA, ROE, ROICAUPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

With an excellent Gross Margin value of 87.25%, AUPH belongs to the best of the industry, outperforming 90.59% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for AUPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AUPH Yearly Profit, Operating, Gross MarginsAUPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10K -20K -30K

More info and screens

5

2. Health

2.1 Basic Checks

AUPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AUPH has more shares outstanding
The number of shares outstanding for AUPH has been increased compared to 5 years ago.
The debt/assets ratio for AUPH is higher compared to a year ago.
AUPH Yearly Shares OutstandingAUPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M
AUPH Yearly Total Debt VS Total AssetsAUPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 2.87 indicates that AUPH is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of AUPH (2.87) is better than 74.42% of its industry peers.
AUPH has a debt to FCF ratio of 2.86. This is a good value and a sign of high solvency as AUPH would need 2.86 years to pay back of all of its debts.
AUPH has a Debt to FCF ratio of 2.86. This is amongst the best in the industry. AUPH outperforms 94.49% of its industry peers.
A Debt/Equity ratio of 0.17 indicates that AUPH is not too dependend on debt financing.
AUPH's Debt to Equity ratio of 0.17 is on the low side compared to the rest of the industry. AUPH is outperformed by 69.80% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF 2.86
Altman-Z 2.87
ROIC/WACCN/A
WACC8.36%
AUPH Yearly LT Debt VS Equity VS FCFAUPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M

2.3 Liquidity

AUPH has a Current Ratio of 5.60. This indicates that AUPH is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 5.60, AUPH perfoms like the industry average, outperforming 58.97% of the companies in the same industry.
AUPH has a Quick Ratio of 5.11. This indicates that AUPH is financially healthy and has no problem in meeting its short term obligations.
AUPH has a Quick ratio (5.11) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.6
Quick Ratio 5.11
AUPH Yearly Current Assets VS Current LiabilitesAUPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 79.25% over the past year.
Looking at the last year, AUPH shows a very strong growth in Revenue. The Revenue has grown by 38.71%.
Measured over the past years, AUPH shows a very strong growth in Revenue. The Revenue has been growing by 222.90% on average per year.
EPS 1Y (TTM)79.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%211.11%
Revenue 1Y (TTM)38.71%
Revenue growth 3Y51.88%
Revenue growth 5Y222.9%
Sales Q2Q%24.32%

3.2 Future

Based on estimates for the next years, AUPH will show a very strong growth in Earnings Per Share. The EPS will grow by 35.45% on average per year.
Based on estimates for the next years, AUPH will show a very strong growth in Revenue. The Revenue will grow by 21.02% on average per year.
EPS Next Y104.91%
EPS Next 2Y75.51%
EPS Next 3Y51.83%
EPS Next 5Y35.45%
Revenue Next Year34.81%
Revenue Next 2Y25.28%
Revenue Next 3Y24.53%
Revenue Next 5Y21.02%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
AUPH Yearly Revenue VS EstimatesAUPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
AUPH Yearly EPS VS EstimatesAUPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 0.5 -0.5 1 -1

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

AUPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 13.59 indicates a correct valuation of AUPH.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AUPH indicates a rather cheap valuation: AUPH is cheaper than 96.80% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of AUPH to the average of the S&P500 Index (22.70), we can say AUPH is valued slightly cheaper.
Industry RankSector Rank
PE N/A
Fwd PE 13.59
AUPH Price Earnings VS Forward Price EarningsAUPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

AUPH's Price/Free Cash Flow ratio is rather cheap when compared to the industry. AUPH is cheaper than 94.85% of the companies in the same industry.
Industry RankSector Rank
P/FCF 40.12
EV/EBITDA N/A
AUPH Per share dataAUPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as AUPH's earnings are expected to grow with 51.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y75.51%
EPS Next 3Y51.83%

More info and screens

0

5. Dividend

5.1 Amount

AUPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AURINIA PHARMACEUTICALS INC

NASDAQ:AUPH (2/21/2025, 8:02:16 PM)

After market: 7.93 0 (0%)

7.93

+0.1 (+1.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)03-04 2025-03-04/amc
Inst Owners41.89%
Inst Owner Change-97.52%
Ins Owners1.92%
Ins Owner Change1.32%
Market Cap1.14B
Analysts81.54
Price Target11.02 (38.97%)
Short Float %7.09%
Short Ratio7.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)285.64%
Min EPS beat(2)17.69%
Max EPS beat(2)553.6%
EPS beat(4)3
Avg EPS beat(4)158.93%
Min EPS beat(4)-14.05%
Max EPS beat(4)553.6%
EPS beat(8)7
Avg EPS beat(8)99.47%
EPS beat(12)10
Avg EPS beat(12)71.73%
EPS beat(16)12
Avg EPS beat(16)57.43%
Revenue beat(2)2
Avg Revenue beat(2)8.5%
Min Revenue beat(2)1.84%
Max Revenue beat(2)15.16%
Revenue beat(4)3
Avg Revenue beat(4)5.17%
Min Revenue beat(4)-0.26%
Max Revenue beat(4)15.16%
Revenue beat(8)7
Avg Revenue beat(8)10.94%
Revenue beat(12)11
Avg Revenue beat(12)12.67%
Revenue beat(16)14
Avg Revenue beat(16)10219.9%
PT rev (1m)-0.25%
PT rev (3m)-0.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)122.79%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 13.59
P/S 5.15
P/FCF 40.12
P/OCF 39.72
P/B 2.93
P/tB 2.96
EV/EBITDA N/A
EPS(TTM)-0.11
EYN/A
EPS(NY)0.58
Fwd EY7.36%
FCF(TTM)0.2
FCFY2.49%
OCF(TTM)0.2
OCFY2.52%
SpS1.54
BVpS2.71
TBVpS2.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.11%
ROE -5.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.25%
FCFM 12.84%
ROA(3y)-23.51%
ROA(5y)-23.99%
ROE(3y)-28.37%
ROE(5y)-27.98%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF 2.86
Debt/EBITDA N/A
Cap/Depr 1.45%
Cap/Sales 0.13%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.6
Quick Ratio 5.11
Altman-Z 2.87
F-Score6
WACC8.36%
ROIC/WACCN/A
Cap/Depr(3y)23.74%
Cap/Depr(5y)123.11%
Cap/Sales(3y)1.3%
Cap/Sales(5y)10.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%211.11%
EPS Next Y104.91%
EPS Next 2Y75.51%
EPS Next 3Y51.83%
EPS Next 5Y35.45%
Revenue 1Y (TTM)38.71%
Revenue growth 3Y51.88%
Revenue growth 5Y222.9%
Sales Q2Q%24.32%
Revenue Next Year34.81%
Revenue Next 2Y25.28%
Revenue Next 3Y24.53%
Revenue Next 5Y21.02%
EBIT growth 1Y72.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year145.3%
EBIT Next 3Y61.43%
EBIT Next 5YN/A
FCF growth 1Y124.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y124.66%
OCF growth 3YN/A
OCF growth 5YN/A